Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of RTS,S/AS01E malaria vaccine safety and immunogenicity in healthy children
PACTR202503849420187Phase 2Recruiting
- Sponsor
- GSK
- Start
- Jun 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of plasmodium falciparum and hepatitis b vaccine (recombinant, adjuvanted) in malaria, sponsored by GSK. Primary endpoint: Immunogenicity profile of RTS,S/AS01E with different doses and schedules. Started Jun 2025; status: recruiting.
02
Drugs
plasmodium falciparum and hepatitis b vaccine (recombinant, adjuvanted)
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR202503849420187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202503849420187.